Company Overview
Cellectar Biosciences, Inc. operates as a clinical biopharmaceutical company dedicated to the discovery, development, and commercialization of pharmaceutical agents specifically designed for cancer treatment within the United States market. The firm functions within the broader healthcare sector, focusing on the specialized industry of biotechnology, which implies a reliance on scientific innovation and regulatory approval processes to bring therapeutic products to patients. As of the latest available data, the company holds a market capitalization of $11.45M, employs 11 staff members, and reports no annual revenue figures in its trailing twelve-month period. The combination of a market cap under $15 million and an absence of reported revenue indicates that Cellectar is a micro-cap entity in a high-risk development stage, where capital is primarily allocated toward advancing its lead phospholipid drug conjugate candidate, CLR 131 (iopofosine I-131), through Phase 2 clinical trials rather than generating immediate commercial cash flow.
Financial Health
The company's financial performance over the trailing twelve months is characterized by significant operating losses, with reported net income of $-21,791,036 and EBITDA of $-22,766,248, reflecting the substantial costs associated with clinical research and development before any commercial sales revenue is realized. The gap between N/A revenue and negative net income reveals a cost structure driven entirely by operational expenses and research activities, as the company has not yet generated sufficient sales to cover its cost of goods sold and operating overheads. Free cash flow stands at $-16,425,541, indicating that the company is burning cash to fund its operations and drug development pipeline, which necessitates access to external capital markets or existing reserves to maintain solvency. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet achieved profitability or established a revenue stream large enough to calculate meaningful margins relative to its expenses. On the balance sheet, Cellectar maintains $13.20M in cash against $409,586 in debt, resulting in a debt-to-equity ratio of 4.13, which suggests a highly leveraged financial position relative to equity, although the absolute dollar amount of debt is low. The current ratio is 2.96, indicating that the company possesses 2.96 times more current assets than current liabilities, which provides a buffer for short-term liquidity despite the lack of operating cash flow. Return on Equity is -170.3% and Return on Assets is -71.0%, metrics that reveal management has not yet generated positive returns on the capital invested by shareholders or the assets held by the firm, typical for pre-revenue biotechnology companies.
Valuation Assessment
Valuation multiples for Cellectar Biosciences are distorted by the absence of earnings, with a trailing P/E ratio of N/A and a forward P/E of -0.87, the latter implying that analysts or data providers expect earnings to remain negative or that the company is valued based on negative earnings multiples due to ongoing losses. The price-to-book ratio is 1.43, suggesting that the market values the company at 1.43 times its book value, which may reflect an expectation of future asset appreciation or intangible value not captured on the balance sheet, despite the lack of current revenue. Alternative valuation metrics such as price-to-sales, which is N/A, and EV/EBITDA of -0.03, further highlight that traditional valuation models based on profitability or sales growth are not applicable to this stage of the company's lifecycle. The stock has exhibited significant volatility over the past year, trading between a 52-week high of $20.70 and a 52-week low of $2.45, with the current trading price situated within this wide range reflecting speculative investor sentiment. The beta value of 0.33 indicates that the stock price is less volatile than the broader market, moving with only 33% of the intensity of the market index, which is an anomaly for a micro-cap biotechnology stock and suggests lower systematic risk relative to its peers.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated positive revenue to calculate meaningful growth rates, and consequently, earnings are not growing faster or slower than revenue because neither exists in a positive form. Cellectar Biosciences does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available cash and potential earnings back into its research and development efforts to advance its drug candidates rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage biopharmaceuticals, where capital is prioritized for clinical trials and regulatory filings over shareholder returns. The overall growth and income profile for Cellectar Biosciences is defined by the absence of current income generation and the reliance on capital markets to fund the progression of its lead candidate, CLR 131, through Phase 2 clinical development toward potential commercialization.